Reference

Quantitative EEG in geriatric drug research: a working hypothesis, first results and their relation to clinical symptomatology

Quantitative EEG in geriatric drug research: a working hypothesis, first results and their relation to clinical symptomatology. Matejcek, M.; Knor, K.; Arrigo, A. (Sandoz Ltd., Basel, Switz.). Action Ageing, Proc. Symp., 43-7. Edited by: Davison, A. N.; Hood, N. A. MCS Consult.: Tunbridge Wells, Engl. (English) 1976. CODEN: 36DMAY. DOCUMENT TYPE: Conference CA Section: 1 (Pharmacodynamics) The hydrogenated ergot alakloids DE 145 [64104-05-8] and DN 16-457 (I) [35167-84-1], administered to geriatric patients either acutely (1 and 0.2 mg, i.v., resp.) or chronically (3 .times. 2.5 mg I/day, orally), reversed the deterioration in the electronencephalogram seen in old age. The changes in the electroenephalogram were correlated with clin. improvement of the patients.

Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man

Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Aellig, W. H.; Nuesch, E. (Biol. Med. Res. Div., Sandoz Ltd., Basel, Switz.). Int. J. Clin. Pharmacol. Biopharm., 15(3), 106-12 (English) 1977. CODEN: IJCBDX. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Pharmacokinetic studies were carried out with 9 3H-labeled ergot alkaloids (dihydroergotamine (I) [511-12-6], dihydroergotoxine [11032-41-0], dihydroergostine [3609-19-6], dihydroergocornine [25447-65-8], dihydroergovaline [3036-37-1], dihydroergonine [35167-84-1], ergotamine [113-15-5], 1-methyl-ergotamine [22336-84-1], and bromocriptine [25614-03-3]). Each drug was administered to 6 subjects in a randomized cross-over design as single oral and i.v. doses. Plasma levels and urinary excretion of tritium-labeled material were analyzed on a phenomenol. basis by non-linear regression as a sum of exponentials. All substances showed the highest plasma concn. about 2 h after oral administration. The mean invasion half-life was 0.5 h. The mean elimination half-lives ranged from 1.4-6.2 h for the .alpha.-phase and from 13 to 50 h for the .beta.-phase, the longest values being obsd. with bromocriptine. From cumulative urinary excretion data after oral and after i.v. administration, a quotient of absorption was calcd. Values between 25 and 30% were found for most dihydrogenated drugs, namely dihydroergotamine, dihydroergotoxine, dihydroergostine, and dihydroergocornine, the only exceptions being dihydroergovaline and dihydroergonine, which were less well absorbed. Ergotamine and 1-methyl-ergotamine had an absorption quotient of about 2/3 and bromocriptine was nearly completely absorbed.